ArticleFrontiers in oncology2021
Progesterone Receptor Expression in Meningiomas: Pathological and Prognostic Implications.
Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 2 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- Association of hormone therapy with spheno-orbital meningiomas: bridging evidence and unknowns.Frontiers in oncology · 2026Pooled it
- Biomarkers for prognosis of meningioma patients: A systematic review and meta-analysis.PloS one · 2024Pooled it
- Meningioma enlargement associated with luteinizing hormone-releasing hormone agonist therapy: two cases and supporting in vitro evidence.Brain tumor pathology · 2026Article
- Associations of surgical menopause and hormone replacement therapy with meningioma development.Journal of neuro-oncology · 2026Article
- Double Staining Immunohistochemistry and Digital Pathology: Moving Towards Standardization of the Proliferative Index Evaluation in Meningiomas.Journal of personalized medicine · 2026Article
- Safety profile of progesterone: Insights from an FDA Adverse Event Reporting System (FAERS)-based pharmacovigilance study.The Journal of international medical research · 2026Observational
- Evaluation of Determinants of Intraoperative Blood Loss During Craniotomy for Brain Tumors: A Retrospective Single-Center Cohort Study.Journal of blood medicine · 2026Article
- Peritumoral edema in meningiomas: a review of influencing factors, mechanisms, and management.Frontiers in oncology · 2026Review
- Digital Quantification of Progesterone Receptor Expression in Meningiomas: Associations with WHO Grade and Clinicopathological Features.Turk patoloji dergisi · 2026Article
- Association of tumor locations, clinical manifestations, and histopathological grade in meningioma: a 10-year single-center study.Frontiers in oncology · 2026Article
- Trends in meningioma-related mortality among U.S. adults: A CDC WONDER analysis from 2000 to 2023.Surgical neurology international · 2026Article
- Review
- Meningioma in users of progestogen contraceptives: a disproportionality analysis of the FDA Adverse Event Reporting System (FAERS).European journal of clinical pharmacology · 2025Article
- Depot Medroxyprogesterone Acetate and Risk of Meningioma in the US.JAMA neurology · 2025Article
- The Association Between Medroxyprogesterone Acetate Exposure and Cerebral Meningioma Among a Medicaid Population.Epidemiologia (Basel, Switzerland) · 2025Article
- Article
- Mifepristone achieves tumor suppression and ferroptosis through PR/p53/HO1/GPX4 axis in meningioma cells.Journal of neuro-oncology · 2025Article
- MRI-based deep transfer learning models for predicting progesterone receptor expression in meningioma.Frontiers in oncology · 2025Article
- Single versus multiple reoperations for recurrent intracranial meningiomas.Journal of neuro-oncology · 2024Article
- Predicting meningioma grades and pathologic marker expression via deep learning.European radiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe progesterone receptor (PR) is variably expressed in most meningiomas and was found to have prognostic significance. However, the correlation with patient age, tumor location, time to recurrence, and pattern of regrowth has scarcely been discussed.
methodsA surgical series of 300 patients with meningiomas is reviewed. The PR expression was classified as: 0. absent; 1. low (<15%); 2. moderately low (16-50%); 3. moderately high (51-79%); 4. high (≥80%). The PR values were correlated with the patient age and sex, meningioma location, WHO grade, Ki-67 MIB1, recurrence rate, pattern of recurrence (local-peripheral
resultsThe PR expression has shown lower rate of high expression in the elderly group (p = 0.032) and no sex difference (including premenopausal
conclusionThe higher PR expression in medial skull base meningiomas, the significant correlation with the time to recurrence, the lack of difference of PR expression between premenopausal and postmenopausal women and between local-peripheral
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.